ダウンロード数: 162
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
37_1511.pdf | 514.82 kB | Adobe PDF | 見る/開く |
タイトル: | 前立腺癌内分泌療法の臨床的検討(第5報) 前立腺癌内分泌療法における再燃例の分析 |
その他のタイトル: | Clinical studies on endocrine therapy for prostatic carcinoma (5): Analyses of relapse from endocrine therapy |
著者: | 熊本, 悦明 塚本, 泰司 梅原, 次男 島崎, 淳 布施, 秀樹 大島, 博幸 竹内, 弘幸 吉田, 修 岡田, 謙一郎 斉藤, 泰 金武, 洋 原田, 昌興 田宮, 高宏 |
著者名の別形: | Kumamoto, Yoshiaki Tsukamoto, Taiji Umehara, Tsugio Shimazaki, Jun Fuse, Hideki Ohshima, Hiroyuki Takeuchi, Hiroyuki Yoshida, Osamu Okada, Ken-ichiro Saito, Yasushi Kanetake, Hiroshi Harada, Masaoki Tamiya, Takahiro |
キーワード: | prostatic carcinoma Relapse Erdocrine therapy |
発行日: | Nov-1991 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 37 |
号: | 11 |
開始ページ: | 1511 |
終了ページ: | 1518 |
抄録: | 1)内分泌療法を行った372例中117例に局所, 全身性の再燃を認めた.再燃を認めた症例の1/4は局所再燃であり, 残りは全身性の再燃であった.2)再燃までの期間(平均月数)はstage B:45.9, C:36.8, D:29.3であった.局所腫瘍のみの非再燃率は治療5年目で90%であったが, 全身性の再燃についての5年目の非再燃率はstage C, Dでそれぞれ71.7%, 67.4%であった.3)再燃から癌死までの期間は, stageにかかわらず平均12~21ヵ月であった.4)全身性再燃と内分泌療法の初期総合効果, 病理組織学的所見との関係では, stage Bでは著効例, 有効例が無効例より, SAT 1が2, 3より非再燃率が高かった.stage C, Dでは著効例のみが, 有効例, 無効例より非再燃率が高く, 病理組織学的所見との関係ではstage DでSATのgradeの悪化に伴う非再燃率の低下を認めた Prostate carcinomas are well known to be initially responsive to endocrine therapy. However, a significant number of the patients experience a relapse from endocrine therapy during the follow-up period. We clinically analyzed various aspects of the relapse which indicate a limitation in the effectiveness of endocrine therapy for prostate carcinoma. In a total of 372 patients, 117 (31.5%) had some evidence of local relapse such as regrowth of the primary lesion, or a generalized relapse such as re-elevation of total acid phosphatase, reactivation of previously present metastasis or the new appearance of metastasis, during endocrine therapy. Of these, one-fourth had local relapse alone and the remainder showed generalized relapse. The interval from the start of the treatment to the time of relapse tended to become shorter; 45.9 months (mean) in stage B, 36.8 in stage C and 29.3 in stage D, according to the stage progression. As to the non-relapse rate of the primary lesion, no differences were found among the stage, with the rate being approximately 90% at the fifth year in each stage. However, the generalized relapse-rate tended to increase with the stage progression. In the generalized relapse, the patients of stage C or D showed a non-relapse rate of 71.7% or 67.4%, respectively. Most of the generalized relapse appeared within five years following start of endocrine therapy in these advanced stages. The interval from relapse to prostate carcinoma-related death in patients with the generalized relapse was 9 approximately 21 months, and those in stage D tended to show a a poorer prognosis.(ABSTRACT TRUNCATED AT 250 WORDS) |
URI: | http://hdl.handle.net/2433/117364 |
PubMed ID: | 1767774 |
出現コレクション: | Vol.37 No.11 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。